Clot Retraction Increases Clot Resistance to Fibrinolysis by Condensing α₂-Plasmin Inhibitor Crosslinked to Fibrin

• References

• 1 Sakata Y, Aoki N. Cross-linking of α₂-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-297
• 2 Sakata Y, Aoki N. Significance of cross-linking of α₂-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-542
• 3 Jansen JWCM, Haverkate F, Koopman J, Nieuwenhuis HK, Kluft C, Boschman ThAC. Influence of factor XIIIa activity on human whole blood clot lysis in vitro. Thromb Haemostas 1987; 57: 171-175
• 4 Reed III GL, Matsueda GR, Haber E. Inhibition of clot-bound antiplasmin enhances in vivo thrombolysis. Circulation 1990; 82: 164-168
• 5 Reed GL, Matsueda GR, Haber E. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of α₂-antiplasmin to fibrin. Thromb Haemostas 1992; 68: 315-320
• 6 Tamaki T, Aoki N. Cross-linking of α₂-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor. Biochim Biophys Acta 1981; 661: 280-286
• 7 Ichinose A, Aoki N. Reversible cross-linking of α₂-plasmin inhibitor to fibrinogen by fibrin-stabilizing factor. Biochim Biophys Acta 1982; 706: 158-164
• 8 Plow EF, Collen D. The presence and release of α₂-antiplasmin from human platelets. Blood 1981; 58: 1069-1074
• 9 Kunitada S, FitzGerald GA, Fitzgerald DJ. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 1992; 79: 1420-1427